Nathalie Schicktanz, Christiane Gerhards, Thomas Schlitt, Amanda Aerni, Elia Müggler, Dominique de Quervain, Andreas Papassotiropoulos, Georg Boonen, Juergen Drewe, Veronika Butterweck
{"title":"缬草-啤酒花提取物组合(Ze 91019)对偶发失眠症患者睡眠时间及日间认知和心理参数的影响:一项随机对照可行性试验","authors":"Nathalie Schicktanz, Christiane Gerhards, Thomas Schlitt, Amanda Aerni, Elia Müggler, Dominique de Quervain, Andreas Papassotiropoulos, Georg Boonen, Juergen Drewe, Veronika Butterweck","doi":"10.1002/brb3.70600","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective/Background</h3>\n \n <p>This study evaluated the feasibility of investigating the effect of a valerian and hops-based herbal medication (Ze 91019) on daytime cognitive performance, psychological parameters, and sleep measures in individuals with occasional sleep problems.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A randomized, double-blind, placebo-controlled study was conducted in 40 participants over a 21-day run-in period and a 21-day treatment period. Participants used Fitbit sleep trackers and completed daily online cognitive tests (i.e., reaction time and working memory), and surveys to assess subjective psychological outcomes (i.e., cognitive performance, stress levels, tiredness, mood, quality of life, and motivation).</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The study design proved feasible, with high adherence to the study protocol. Exploratory analyses revealed a statistically significant increase in sleep duration during the treatment period for participants using Ze 91019 compared to placebo (mean daily increase: 21.7 min, <i>p</i> = 0.019) without statistically significant effects on cognitive or psychological outcomes. Moreover, Ze 91019 statistically significantly increased the sleep duration of the shortest night in the treatment period by 48.7 minutes. The medication was well-tolerated.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>The study design proved feasible, and Ze 91019 increased sleep duration without affecting daytime cognitive or psychological outcomes.</p>\n </section>\n \n <section>\n \n <h3> Trial Registration</h3>\n \n <p>The trial has been preregistered at www.clinicaltrials.gov (NCT05684523).</p>\n </section>\n </div>","PeriodicalId":9081,"journal":{"name":"Brain and Behavior","volume":"15 6","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/brb3.70600","citationCount":"0","resultStr":"{\"title\":\"Effects of a Valerian-Hops Extract Combination (Ze 91019) on Sleep Duration and Daytime Cognitive and Psychological Parameters in Occasional Insomnia: A Randomized Controlled Feasibility Trial\",\"authors\":\"Nathalie Schicktanz, Christiane Gerhards, Thomas Schlitt, Amanda Aerni, Elia Müggler, Dominique de Quervain, Andreas Papassotiropoulos, Georg Boonen, Juergen Drewe, Veronika Butterweck\",\"doi\":\"10.1002/brb3.70600\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Objective/Background</h3>\\n \\n <p>This study evaluated the feasibility of investigating the effect of a valerian and hops-based herbal medication (Ze 91019) on daytime cognitive performance, psychological parameters, and sleep measures in individuals with occasional sleep problems.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>A randomized, double-blind, placebo-controlled study was conducted in 40 participants over a 21-day run-in period and a 21-day treatment period. Participants used Fitbit sleep trackers and completed daily online cognitive tests (i.e., reaction time and working memory), and surveys to assess subjective psychological outcomes (i.e., cognitive performance, stress levels, tiredness, mood, quality of life, and motivation).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>The study design proved feasible, with high adherence to the study protocol. Exploratory analyses revealed a statistically significant increase in sleep duration during the treatment period for participants using Ze 91019 compared to placebo (mean daily increase: 21.7 min, <i>p</i> = 0.019) without statistically significant effects on cognitive or psychological outcomes. Moreover, Ze 91019 statistically significantly increased the sleep duration of the shortest night in the treatment period by 48.7 minutes. The medication was well-tolerated.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>The study design proved feasible, and Ze 91019 increased sleep duration without affecting daytime cognitive or psychological outcomes.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Trial Registration</h3>\\n \\n <p>The trial has been preregistered at www.clinicaltrials.gov (NCT05684523).</p>\\n </section>\\n </div>\",\"PeriodicalId\":9081,\"journal\":{\"name\":\"Brain and Behavior\",\"volume\":\"15 6\",\"pages\":\"\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2025-06-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/brb3.70600\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Brain and Behavior\",\"FirstCategoryId\":\"102\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/brb3.70600\",\"RegionNum\":3,\"RegionCategory\":\"心理学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"BEHAVIORAL SCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Brain and Behavior","FirstCategoryId":"102","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/brb3.70600","RegionNum":3,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BEHAVIORAL SCIENCES","Score":null,"Total":0}
Effects of a Valerian-Hops Extract Combination (Ze 91019) on Sleep Duration and Daytime Cognitive and Psychological Parameters in Occasional Insomnia: A Randomized Controlled Feasibility Trial
Objective/Background
This study evaluated the feasibility of investigating the effect of a valerian and hops-based herbal medication (Ze 91019) on daytime cognitive performance, psychological parameters, and sleep measures in individuals with occasional sleep problems.
Methods
A randomized, double-blind, placebo-controlled study was conducted in 40 participants over a 21-day run-in period and a 21-day treatment period. Participants used Fitbit sleep trackers and completed daily online cognitive tests (i.e., reaction time and working memory), and surveys to assess subjective psychological outcomes (i.e., cognitive performance, stress levels, tiredness, mood, quality of life, and motivation).
Results
The study design proved feasible, with high adherence to the study protocol. Exploratory analyses revealed a statistically significant increase in sleep duration during the treatment period for participants using Ze 91019 compared to placebo (mean daily increase: 21.7 min, p = 0.019) without statistically significant effects on cognitive or psychological outcomes. Moreover, Ze 91019 statistically significantly increased the sleep duration of the shortest night in the treatment period by 48.7 minutes. The medication was well-tolerated.
Conclusions
The study design proved feasible, and Ze 91019 increased sleep duration without affecting daytime cognitive or psychological outcomes.
Trial Registration
The trial has been preregistered at www.clinicaltrials.gov (NCT05684523).
期刊介绍:
Brain and Behavior is supported by other journals published by Wiley, including a number of society-owned journals. The journals listed below support Brain and Behavior and participate in the Manuscript Transfer Program by referring articles of suitable quality and offering authors the option to have their paper, with any peer review reports, automatically transferred to Brain and Behavior.
* [Acta Psychiatrica Scandinavica](https://publons.com/journal/1366/acta-psychiatrica-scandinavica)
* [Addiction Biology](https://publons.com/journal/1523/addiction-biology)
* [Aggressive Behavior](https://publons.com/journal/3611/aggressive-behavior)
* [Brain Pathology](https://publons.com/journal/1787/brain-pathology)
* [Child: Care, Health and Development](https://publons.com/journal/6111/child-care-health-and-development)
* [Criminal Behaviour and Mental Health](https://publons.com/journal/3839/criminal-behaviour-and-mental-health)
* [Depression and Anxiety](https://publons.com/journal/1528/depression-and-anxiety)
* Developmental Neurobiology
* [Developmental Science](https://publons.com/journal/1069/developmental-science)
* [European Journal of Neuroscience](https://publons.com/journal/1441/european-journal-of-neuroscience)
* [Genes, Brain and Behavior](https://publons.com/journal/1635/genes-brain-and-behavior)
* [GLIA](https://publons.com/journal/1287/glia)
* [Hippocampus](https://publons.com/journal/1056/hippocampus)
* [Human Brain Mapping](https://publons.com/journal/500/human-brain-mapping)
* [Journal for the Theory of Social Behaviour](https://publons.com/journal/7330/journal-for-the-theory-of-social-behaviour)
* [Journal of Comparative Neurology](https://publons.com/journal/1306/journal-of-comparative-neurology)
* [Journal of Neuroimaging](https://publons.com/journal/6379/journal-of-neuroimaging)
* [Journal of Neuroscience Research](https://publons.com/journal/2778/journal-of-neuroscience-research)
* [Journal of Organizational Behavior](https://publons.com/journal/1123/journal-of-organizational-behavior)
* [Journal of the Peripheral Nervous System](https://publons.com/journal/3929/journal-of-the-peripheral-nervous-system)
* [Muscle & Nerve](https://publons.com/journal/4448/muscle-and-nerve)
* [Neural Pathology and Applied Neurobiology](https://publons.com/journal/2401/neuropathology-and-applied-neurobiology)